MarginsXMarginsX
Home › Markets › Health Care › COSM

Cosmos Health Inc. (COSM)

COSM trades on Nasdaq in Health Care, Other Pharmaceuticals. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.49
-23.15% on the day
Market cap
$250.6M
Micro cap
Revenue · 2025
$65.3M
+19.9% on 2024
Net income · 2025
-$19.1M
-29.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1474167/000147793226002278/0001477932-26-002278-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerCOSM on Nasdaq
SectorHealth Care
IndustryOther Pharmaceuticals
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001474167

Financials · 2025

LineValue
Revenue$65.3M
Net income-$19.1M
Operating income-$16.7M
Net margin-29.3%
Operating margin-25.6%
Revenue growth+19.9%
Cash$716K
Total assets$65.5M
P/E (computed)Net income was not positive
P/S (computed)3.8×

Warning signs

Cash runway
2.2 months
$1.8M cash at June 30, 2026
Share count, 1 year
+233.1%
2025-08-14 to 2026-08-18 · +847.5% over 3 years
Going-concern doubt
Yes
10-Q filed August 18, 2026
Insider net buying, 12 months
$1.7M
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of 12 months from the date of this filing."
10-Q 2026-08-18
Cash and burn$1.8M cash; operating cash flow -$2.5M a quarter.Report 2026-06-30
Shares outstandingNo cover-page share count in XBRLCover page 2026-08-18
Reverse splits, 3 years1; latest 1-for-20 on 2026-11-13Source 2026-11-13
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2025-12-18
AuditorRBSM LLP, NEW YORK, New York, United StatesPCAOB Form AP 2026-04-16
Late filings, 12 months3 NT noticesNT 10-Q 2026-08-14
Insider trades, 12 monthsBought $1.7M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$19.0M-$6.1M-$1.7M$1.8M$3.2M$73.7M10-Q 2026-08-18
Q1 2026
2026-03-31
$17.9M-$2.8M-$1.1M$515K$3.5M$69.5M10-Q 2026-05-20
Q4 2025
2025-12-31
$19.7M-$10.1M-$4.6M$716K$3.8M$65.3M10-K 2026-04-15
Q3 2025
2025-09-30
$17.1M-$5.4M-$2.5M$889K$5.4M$59.8M10-Q 2025-11-14
Q2 2025
2025-06-30
$14.7M-$2.8M-$1.2M$656K$5.2M$55.1M10-Q 2026-08-18
Q1 2025
2025-03-31
$13.7M-$818K-$186K$743K$4.9M$53.6M10-Q 2026-05-20
Q4 2024
2024-12-31
$14.2M-$3.3M-$3.8M$315K$4.1M$54.4M10-K 2026-04-15
Q3 2024
2024-09-30
$12.4M-$8.4M$740K$3.3M$4.3M$56.0M10-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week-28.3%
1 month-40.6%
3 months+0.5%
Year to date-58.2%
1 year-71.5%
From 52-week high-71.4%

Source: Yahoo Finance daily closes, last bar 2026-11-12. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Other Pharmaceuticals

TickerCompanyPriceDayMarket cap
NUSNu Skin Enterprises Inc.$3.93-2.48%$191.3M
ZSTKZeroStack Corp.$2.80-1.75%$61.1M
ESYNEnerSyn Global Inc.$1.250.00%$37.2M
HLFHerbalife Ltd. Common Shares$16.15+1.19%$1.7B
HKPDCellyan Biotechnology Co. Ltd$1.61-0.62%$4.0M
MEDSDataMeds AI Inc.$0.6421-13.68%$3.1M
CAHCardinal Health Inc.$283.85+0.98%$65.6B
CORCencora Inc.$356.94-0.58%$68.1B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier